🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Synthetic biology just jumped from hype to health impact: base-edited LDL drugs cut 53–69% cholesterol in humans, Congress tabled a National Biotechnology Initiative, and investment is rebounding. 🧬🚀 VERVE-102’s one-shot base editing slashed LDL in early trials (avg −53%, up

Vipin M. Vashishtha The findings you mention highlight the persistent immune response in #LongCOVID patients, raising questions about how these ongoing inflammatory and interferon pathways might be contributing to the symptoms that persist long after the acute phase of the virus. Could these

Cancer is heating up—literally. Magnetic hyperthermia is racing from bench to bedside. 🔥🧲 Why now? JAMA: 35.3 M cases by 2050 (+76.6%). A 2025 RSC review reports smarter iron-oxide nanoheaters carrying drugs/MRI contrast. ([JAMA Network][1], [RSC Publishing][2]) Spring ’25

RA care is pivoting to biosimilars—now. Jan 2025 FDA okayed Avtozma (tocilizumab) for RA, and in 2025 CMS lets Part D plans swap originators mid-year; PBM shifts in Apr 2024 already flipped Humira scripts. 💊 ([morganlewis.com][1], [Centers for Medicare & Medicaid

CRISPR just leapt from first approval to a wave of one-and-done edits—regulators are speeding up, data are maturing, payers are circling. 🧬🚀 Dec 2023: FDA okays CASGEVY, first CRISPR/Cas9 therapy for sickle cell. Mar 2025: FDA grants RMAT to Intellia’s in-vivo ATTR candidate

Smart pills just leapt from sci-fi to reimbursement reality: CMS is widening RPM coverage in 2025 while an opioid “digital pill” trial showed real-time adherence in acute pain patients. Ready to swallow the future? 🚀 CMS spend on RPM soared $15M→$300M (2019–2022) and Medicare

AI diagnostics is about to get stress-tested—by regulators, clinicians, and patients. ⏱️👀🧪 EU says there’s “no pause” on the AI Act deadlines—general-purpose/high-risk models face binding rules from Aug 2, 2025. Meanwhile, FDA issued fresh AI-device guidance in May outlining

Clinics hand out bands as patients retrain in headsets. 🚀 This week an RCT showed VR-enhanced cognitive rehab beat usual care—why are programs analog? ([BioMed Central][1]) 2025 RCTs (BMC Psych, JNER) show VR boosts cognition & UL recovery. 🧠🦾 FDA lists 90+ AR/VR devices

Prescription apps aren’t sci‑fi anymore: FDA okayed the first DTx for depression, CMS just added 2025 Medicare codes, and NICE says digital CBT can free therapist hours. 🚀. ([Otsuka US][1], [Xealth][2], [NICE][3]) 1 in 8 people live with a mental disorder, yet care gaps

MRI is breaking free from fortress walls: FDA‑cleared portable scanners, ultra‑high‑field 7 T imaging, and AI that rebuilds scans in seconds are remapping diagnostic frontiers 🧲🚀 June’s FDA green‑light for Hyperfine’s Swoop puts AI‑powered, socket‑plugged brain MRI at the

Neurofeedback for ADHD just got its toughest reality check—and its biggest opening. 🔄🧠 A Dec 2024 JAMA Psychiatry meta‑analysis (38 RCTs, 2.4 k pts) saw no blinded symptom gain vs sham—only modest processing‑speed lift.💡[1] ([King's College London][1]) Still, Feb 2025 AAP

Paraplegics walking months after injury? The spinal cord comeback is outrunning MRI scans—update your playbooks fast. 🧠 Jan‑25: 60 % spasticity drop and walker use in 3 wks via high‑freq epidural stim([ScienceDaily][1]). Neuralink’s 5th chip now lets a vet text by

🧬 Hit “print” on living tissue: 3D bioprinting is leaping from lab bench to OR, rewriting how we patch hearts, bones, and skin. In January, scientists printed beating human‑like heart tissue that stayed alive for weeks—proof of concept for custom cardiac patches.

Regrowing cartilage isn’t sci‑fi—gene edits & stem cells are shaking up osteoarthritis care. 🚀🦴 📈 FDA RMAT (16 Jul 25) vaulted IL‑1 gene therapy GNSC‑001 toward approval.([BioPharm International][1]) Meta‑analysis (Mar 25) of 18 RCTs: MSC shots cut knee pain 40

Rheumatology is finally riding the precision‑medicine wave—replacing trial‑and‑error scripts with data‑guided care.🧬 The Lancet Rheumatology just showed CPL’116 (dual JAK/ROCK) hit 70% ACR20 in biomarker‑picked RA at 12 w.([The Lancet][1]) At EULAR 2025, Scipher’s AI “RA

An inhaler that logs every puff, predicts flares, pages your clinician, and coaches technique in real time—smart inhalers are jumping from pilot to routine use in 2025, reshaping asthma care. This week the FDA cleared Adherium’s Hailie sensor for AZ’s Airsupra & Breztri,

Spray‑on cells, gene‑edited sheets, 3D‑printed skin—grafts are sprinting into the bioprinter age, landing on wounds before scars do, and the implications for burn and rare‑disease care are enormous. 🩹✨ June 2025: Stanford phase III gene‑therapy grafts closed 70 % of chronic

Stents are evolving—dissolving, polymer‑free, ultra‑thin. Cath labs, take note 👀 Feb 2025 RCT (2,107 PCI pts): polymer‑free amphilimus stent matched bio‑polymer EES on MACE at 1 yr, yet thrombosis ×3.([European Medical Journal][1]) May 2025 SORT‑OUT XII: 60 µm ultra‑thin

From blanket chemo to AI printers turning your tumor’s genome into a bespoke mRNA shot in <6 weeks—the cancer‑vaccine era is no longer future talk, and regulators are scrambling to keep pace.👇 🎯 ASCO 2025: mRNA‑4157+Keytruda cut distant‑met/death 65 % in high‑risk

AI imaging isn’t coming—it’s here: FDA logged 100+ new radiology algorithms this month 🔬🚀 July 10: FDA list tops 800 AI imaging tools([Health Imaging][1]); July 16: RIVANNA Accuro 3S ultrasound earns 510(k)([tmcnet.com][2]). Market $1.36 B today, set for